Copeland's Dickson buy adds cloud-native monitoring as the pharma cold chain moves toward continuous visibility to meet rising regulatory demands.
|Articles|September 22, 2015
- Pharmaceutical Commerce - September/October 2015
Cold Chain 2015 Directory
Advertisement
Articles in this issue
about 11 years ago
Maintaining your digital marketing assetsabout 11 years ago
Cold Chain Global Forum takes shapeabout 11 years ago
Driving Traceability Requirements to True Business Valueabout 11 years ago
Next-Generation Serializationabout 11 years ago
A Conversation with Steve Collis, AmerisourceBergenabout 11 years ago
The quality drive at contract manufacturersabout 11 years ago
The 2015 Biopharma Cold Chain Landscapeabout 11 years ago
Pharma is under-managing its multi-channel marketing effortsabout 11 years ago
Predicting pharma's data-driven futureAdvertisement
Related to this article
In this week's Pharma Pulse, Vicapsys merges with Stateline, Veritiv targets GLP-1 shipping, Section 232 tariffs widen and HRSA's 340B rebate pilot deadline arrives.
Temperature excursions cost pharma an estimated $35 billion a year as biologics, GLP-1s and cell and gene therapies raise cold chain stakes.
Go behind the scenes of LogiPharma USA 2026 with program director Charleen Ring and McKesson's Chris Van Norman in this Pharma Pulse special.
In this week's Pharma Pulse, DHL breaks ground on a new cold chain hub at Singapore's Changi Airport, a new report finds pharma's commercial model in the middle of a fundamental reset, and the FDA grants accelerated approval to sevabertinib.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
FAQ: What Comes Next for the 340B Rebate Pilot
2
Pharma Pulse: Vicapsys-Stateline Merger and Veritiv's TempSafe RxShield
3
Why Early, Big-Picture Planning Is Key to Execution Across the CGT Lifecycle
4
How Early Development Decisions Shape Commercial Readiness for Biologics
5